PMD is #MakingEveryBreathCount improving patient outcomes & safety with RespiraSense, a revolutionary sensor platform for continuous respiratory rate monitoring

Making Every Breath Count!

At PMD we have a motto that sums up our intent and the premise on which our company was established…..

Making Every Breath Count!

TEAM
  • Myles Murray
    CEO - Myles Murray

    Myles Murray is the Founder and Chief Executive Officer of PMD Solutions. Being a highly motivated and focused individual Myles is developing PMD Solutions as a high momentum medical device company. Since 2011, Myles has developed novel technology that will revolutionise the way healthcare providers measure patient breathing. With an international focus, Myles is engaging PMD with the medical community across Europe to prepare ‘RespiraSense’ – Breathing Frequency Monitor – for its market launch. Through developing collaborative relationships with foreign and domestic companies, Myles has excelled PMD’s time to market.

    • Anne Dorney
      CFO - Anne Dorney

      Anne Dorney, Chief Financial Officer of PMD Solutions, is a former Bank Manager with over 30 years banking experience, taking early retirement from AIB in 2012. Qualified Lender & Financial advisor through the Institute of Bankers in Ireland. She has over 25 years’ retail, commercial & industrial lending experience dealing with companies of all sizes from small start-ups to large international corporate companies. She has vast experience in identifying, supporting & mentoring start- up businesses from incubation stage through to commercial maturity. Strong analytical, compliance and management skills developed in the competitive banking industry at managerial levels for 25 years. Anne also holds a FETAC approved diploma in office administration.

      • Séan Kinsella
        CTO - Séan Kinsella

        Seán is PMD’s CTO and is responsible for leading the technology strategy and product roadmap which will bring to market innovative medical devices that will make every breath count. Prior to joining PMD, Seán worked as Chief Analyst at S3 Group on a Connected Health Platform designed to engage patients with chronic diseases and provide insights to payers through the use of real world evidence. He has vast experience in the design and development of medical devices, is a proponent of user centred design and is passionate about pursuing innovative and emerging technologies to save lives. Seán holds a B.Eng in Electronic Engineering from Dublin City University and an MSc. by Research from Cork Institute of Technology in the field of robotics.

        • Medical Advisory Committee
          Medical Advisory Committee

          Leading PMD Solutions’ Medical Advisory Committee include Professor Stephen Cusack and Dr. John Kellett, leaders in the field of emergency and internal medicine with decades of practicing and researching of the leading methodologies of early warning, rapid response, and general patient monitoring techniques.

          • R & D Team
            R & D Team

            PMD Solutions’ Research & Development team is comprised of exceptional individuals, experts in the fields of Electronic Design, Digital Signal Processing, Software Development (Mobile Application and Cloud), Clinical Investigation Management, Quality Management (DDP and QMS), and Industrial Design.

            WHO WE ARE

            WHO WE ARE

            Making Every Breath Count!

            PMD was founded to void the fundamental clinical need to measure patients breathing rates, which if amiss, is a significant indicator of an adverse event.

            During 2010, working with Cork University Hospital’s Emergency Department and resident Professor of Emergency Medicine, Mr Stephen Cusack, we developed a new to world technology that revolutionises the way this lost vital sign is measured.

            Our solutions improve patient care and medical outcomes across the globe.

            Since its inception PMD has developed ground breaking medical devices for the monitoring and diagnosis of respiratory conditions with the fundamental belief of making every breath count.

            PMD is #MakingEveryBreathCount improving patient outcomes & safety with RespiraSense, a revolutionary sensor platform for continuous respiratory rate monitoring
            HISTORY

            Innovative & Patient Friendly Technologies

            PMD Solutions, founded in 2011, develop innovative and patient friendly technologies to support health provider’s early prevention model of patient care. PMD continues its operations in Bishopstown House, Model Farm Road, Cork, Ireland.

            PMD was founded on a fundamental clinical need to measure a patients breathing rate, which if amiss, is a significant indicator that something is wrong with the patient. During 2010, working with Cork University Hospital’s Emergency Department and resident Professor of Emergency Medicine Stephen Cusack, PMD developed a viable technology to revolutionise the way this lost vital sign was measured. Since then, PMD has developed ground breaking medical devices for the monitoring and diagnosis of respiratory conditions with the fundamental belief of making every breath count, PMD can improve patient outcomes.

            Numerous Clinical Applications

            While the core technology has several clinical applications today, the primary focus of the technology was to address the technological deficit of accurate and continuous respiratory rate monitoring. Since early 2000, healthcare systems around the world were trying to adapt to manage an ageing population and reducing healthcare budgets. From this economic pressure came the focus on preventative monitoring – the ability to risk stratify patients according to probable level of future severity. This is known as Early Warning Scoring. The measuring of several vital signs including Respiratory Rate, Heart Rate, Blood Pressure, Temperature, and Blood Oxygen Levels.

            Although the significance of respiratory rate monitoring as the earliest and most sensitive indicator of patient deterioration had been well published as far back as the 1920’s, the infrastructure for acting upon with was enabled through the deployment of Early Warning Scoring. Further research development from 2010 onwards began to quantify respiratory rates early and specific predictors of patient outcomes including a study by Dr. Goldhill, anaesthetist of The Royal National Orthapaedic Hospital, Stanmore, UK, reports that 21% of patients having an RR of between 25-29 breath per minute had an event, with said indictor showing 24 hours before the adverse event, ahead of any other change in the other vital signs, with 95% specificity.

            94% of the Population Suffer from Sleep Apnoea

            Since the launch of RespiraSense in 2014, PMD has continued its research activities to launch a new product in 2016 that seeks to address the undiagnosed 94% of the population suffering with Sleep disorders. Sleep apnoea, a condition resulting in breaks in breathing effort during sleep, has significant health and lifestyle implications if left untreated. Today, 3-4% of the global population suffers from sleep apnoea with 94% still waiting to be tested, diagnosed, and prescribed a treatment such a Continuous Positive Airway Pressure (CPAP).  PMD has leveraged the same technology used for continuous respiratory rate monitoring in the form of a Home Sleep Test – no more belts and no more nasal cannulas. Just apply, and within 24 hours of the test being completed, treatment can be prescribed. More importantly, it will enable sleep consultants to increase their patient coverage by over 200% with minimum increase in resources.

            Early identification of patient deterioration

            The value of respiratory rate monitoring for the early identification of patient deterioration is evident and the clinical need for accelerated diagnosis for sleep apnoea is urgent. PMD seeks to improve patient’s outcomes by making every breath count through continuous Respiratory rate monitoring for general care floor and simple home sleep Tests for patients around the world. Positioning PMD’s technology as the industry standard in respiratory effort monitoring by 2020.

            Timeline
            2010
            Aug 11

            PMD is Born

            Product trial in Cork University Hospital

            2011
            Aug 11

            PMD has Arrived

            PMD Solutions develops its first working prototype

            Sep 11

            Clinical Director

            PMD appoints Stephen Cusack as the company’s Clinical Director

            Oct 11

            Enterprise Programme

            PMD is selected for the Genesis Enterprise Program

            2012
            Mar 11

            Finalist

            PMD graduates from the GE programme as a finalist of the Genesis Enterprise Emerging Business of the Year award

            May 11

            Awarded Best of Class

            PMD awarded Best of Class at Cork Entrepreneurial Experience

            2013
            Jun 11

            NDRC’s VentureLab

            Awarded a founding place on the NDRC’s VentureLab program

            Jul 11

            Joining of Forces

            PMD and Gentian Services join resources to bring RespiraSense to commercialisation

            Sep 11

            InterTradeIreland

            Wins Highly Commended Award from Intertrade Ireland All-Island Seedcorn Competition

            Oct 11

            Seed Round Success

            PMD raises €450,000 through Enterprise Ireland, Industrial, and Angel investment

            2014
            Jan 11

            Clinical Trial

            RepiraSense performs expertly during clinical trial in UHC

            Feb 11

            Entering HPSU Space

            PMD is awarded Enterprise Ireland High Potential Start-Up status

            Apr 11

            On the Medtech Map

            PMD attends Medtec for the first time

            Aug 11

            MedTec Award

            Start-Up Academy of Excellence Winner

            Aug 11

            Finalist

            IMDA Medical Technology Industry Excellence Emerging Company of the Year

            2015
            Sep 11

            CE Mark

            RespiraSense gets CE Mark approval

            Sep 11

            Funding Injection

            PMD secures €4.2 million in funding from Horizon 2020 SME Instrument

            2016
            Mar 11

            DotMed Award

            PMD wins dotMED 2016 Health Technology award

            Jul 11

            RespiraSense Hits Australia

            PMD attends 12th International Conference on Rapid Response Systems and Medical Emergency Teams in Melbourne

            2017
            Feb 02

            PMD Solutions Announces Successful FDA Pre Submission Meeting and Progresses with Plans for FDA 510K Submission in 2017 ‘RespiraSense’

            PMD Solutions Announces Successful FDA Pre Submission Meeting and Progresses with Plans for FDA 510K Submission in 2017 ‘RespiraSense’ PMD Solutions, an Irish Medical Technology firm, announces a successful Pre Submission meeting with the FDA for ‘RespiraSense’, the world’s first respiratory rate wearable specifically designed for trend monitoring of acute…